A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
第2相
完了
NCT05775289
| 対象疾患 | Non-small Cell Lung Cancer |
|---|
| 相 | 第2相 |
|---|
| スポンサー | Hoffmann-La Roche |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 182 名 |
|---|
| 介入（薬剤） | Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin |
|---|
| 開始日 | 2023年3月15日 |
|---|
| 完了日 | 2024年6月20日 |
|---|
| 結果公開日 | 2025年11月19日 |
|---|
概要
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.
Progression-Free Survival (PFS)
Randomization to date of first documented disease progression or death (up to approximately 15 months) · Months
| Pembro + Chemotherapy | 7.13 Months |
|---|
| Tobe + Chemotherapy | 7.62 Months |
|---|
| p-value | 0.9705 |
|---|
| Hazard Ratio (HR) | 0.99 (95% CI 0.63–1.56) |
|---|
Objective Response Rate (ORR)
Up to approximately 15 months · Percent of participants
| Pembro + Chemotherapy | 46.2 Percent of participants |
|---|
| Tobe + Chemotherapy | 41.1 Percent of participants |
|---|
| p-value | 0.4056 |
|---|
| Odds Ratio (OR) | 0.77 (95% CI 0.42–1.43) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。